McKinsey Seeks to Avoid New Succession Dramas With Changes to Its Elections
The elite consulting firm, as part of sweeping changes to its governance, will now elect a global managing partner to a single six-year term, though its partners will hold a confirmation vote at the four-year mark on whether the leader should serve the final two years of that term. McKinsey's roughly 750 senior partners currently vote to elect a firmwide leader every three years and can stand for two terms.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Eastern Bankshares Inc (EBC) Q2 2025 Earnings Call Highlights: Strong Growth in Earnings and ...
Operating Earnings: $81.7 million, a 21% increase from the first quarter. Net Interest Margin: Expanded by 21 basis points to 3.59%. Operating Efficiency Ratio: Improved to 50.8%. Operating Return on Average Assets: Increased by 21 basis points to 1.3%. Operating Return on Average Tangible Equity: Increased from 11.7% to 13.6%. Total Assets: $25.5 billion, up 2% from March 31. Tangible Book Value Per Share: Increased 4% to $12.53. Loan Growth: 8% annualized growth this quarter. Deposits Growth: 8% annualized growth. Assets Under Management: Reached a record high of $8.7 billion. Net Income: $100.2 million or $0.50 per diluted share. Operating Earnings Per Share: $0.41, a 21% increase from the previous quarter. Net Interest Income: $202 million, or $206.8 million on an FTE basis, a 7% increase from Q1. Non-Interest Income: $42.9 million, compared to a non-interest loss of $236.1 million in Q1. Non-Interest Expense: $137 million, an increase of $6.8 million from the first quarter. Period End Deposits: $21.2 billion, an increase of $424 million from the prior quarter. Period End Loans: Increased by $385 million, led by commercial lending. Allowance for Loan Losses: $232 million or 127 basis points of total loans. Non-Performing Loans: Decreased to $54.7 million or 30 basis points of total loans. Provision for Loan Losses: $7.6 million, up from $6.6 million in the prior quarter. Full Year Loan Growth Outlook: Raised to 3% to 5%. Full Year Deposit Growth Expectation: Lowered to 0% to 1%. Net Interest Income Guidance: $810 million to $820 million. Operating Fee Income Forecast: Increased to $145 million to $150 million. Operating Non-Interest Expense Forecast: $530 million to $540 million. Operating Tax Rate: Revised to 21% to 22%. Warning! GuruFocus has detected 6 Warning Signs with COLFF. Release Date: July 25, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Eastern Bankshares Inc (NASDAQ:EBC) reported strong second quarter results with operating earnings of $81.7 million, a 21% increase from the first quarter. Net interest margin expanded by 21 basis points to 3.59%, and the operating efficiency ratio improved to 50.8% due to higher revenues and effective expense management. Total assets reached $25.5 billion, up 2% from March 31, with tangible book value per share increasing by 4% to $12.53. Deposits grew at an annualized rate of 8%, with stable deposit costs, highlighting disciplined pricing and a favorable deposit mix. Credit trends remained positive, with non-performing loans improving for the second consecutive quarter and no net charge-offs reported. Negative Points The competitive market for deposits has intensified, impacting the bank's ability to maintain favorable deposit costs. The bank's outlook for deposit growth has been lowered to 0% to 1%, down from the previous range of 1% to 2%. The net interest income guidance has been modestly reduced due to lower average deposit balances. Non-interest expense increased by $6.8 million from the first quarter, driven by higher operating expenses and merger-related costs. The bank remains cautious about economic uncertainties and evolving policies that could impact customers. Q & A Highlights Q: Is it likely that we'll see more securities portfolio restructurings in coming quarters, excluding any related to the Harbor One deal? A: Possibly. We prioritize organic growth, share buybacks, and balance sheet management, including portfolio repositioning. However, due to the merger and the expiration of our current authorization, restructuring is on the back burner for now. - David Rosato, Chief Financial Officer Q: What drove the significant drop in non-performing loans (NPLs) this quarter? Were there any loan sales involved? A: The drop was due to our managed asset group resolving five credits during the quarter, not through loan sales. - David Rosato, Chief Financial Officer Q: Following the Harbor One deal, is there a plan to expand into new markets like Southern Rhode Island, Connecticut, or New York? A: We plan to build out in the Rhode Island market but have no current plans to expand banking services into Connecticut or New York. We already have a presence in Connecticut for wealth management. - Denis Sheahan, Chief Executive Officer Q: Can you provide more details on the strong CNI growth this quarter? What type of customers were involved, and were these new customers or existing ones utilizing more credit? A: It's a combination of both. We're seeing increased confidence from our customer base and have been adding talent in our commercial lending division. The growth is broad-based across all verticals within CNI. - Denis Sheahan, Chief Executive Officer and David Rosato, Chief Financial Officer Q: What is the outlook for the net interest margin in the back half of the year? A: The margin is expected to be relatively flat. Factors include core deposit growth, the impact of securities repositioning, and competitive deposit markets. Accretion income is unpredictable and could affect the margin. - David Rosato, Chief Financial Officer Q: How should we think about the rabbi trust income and its impact on fee income and expenses for the full year? A: Positive equity markets lead to positive rabbi trust income. If markets remain steady, the rabbi trust income and expense won't significantly impact the financials. - David Rosato, Chief Financial Officer Q: Are any of the $118 million in criticized office loans maturing in the next four quarters? A: Yes, there is one criticized loan maturing within the next year. However, there are no non-performing loans or non-accruing loans in the next year's maturities. - David Rosato, Chief Financial Officer Q: Regarding the FASB's proposed ASU on the CECL double count, what will the tangible book pickup look like, and will you be an early adopter? A: If finalized, we plan to early adopt, which applies only to Harbor One. The impact is a 1% to 1.5% reduction in tangible book value dilution and a slight reduction in earn-back time. - David Rosato, Chief Financial Officer For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
HCA Healthcare Inc (HCA) Q2 2025 Earnings Call Highlights: Strong EPS Growth and Strategic ...
Diluted Earnings Per Share: Increased 24% to $6.84. Revenue Growth: 6.4% increase driven by greater demand, improved payer mix, and consistent patient acuity levels. Equivalent Admissions: Increased 1.7% for the quarter and 2.3% for the year. Managed Care Equivalent Admissions: Grew 4% year-to-date. Medicare Growth: 3%, slightly below expectations. Adjusted EBITDA Margin: Improved by 30 basis points compared to the prior-year quarter. Adjusted EBITDA Growth: 8.4% over the prior-year quarter. Cash Flow from Operations: $4.2 billion in the quarter. Capital Expenditures: $1.2 billion in the second quarter. Share Repurchases: $2.5 billion in the second quarter. Dividends: $171 million in the second quarter. 2025 Revenue Guidance: Expected to range between $74 billion and $76 billion. 2025 Net Income Guidance: Expected to range between $6.11 billion and $6.48 billion. 2025 Adjusted EBITDA Guidance: Expected to range between $14.7 billion and $15.3 billion. 2025 Diluted EPS Guidance: Expected to range between $25.50 and $27. 2025 Capital Spending Guidance: Approximately $5 billion. Warning! GuruFocus has detected 4 Warning Signs with UVE. Release Date: July 25, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points HCA Healthcare Inc (NYSE:HCA) reported a strong financial performance for the second quarter of 2025, with a 24% increase in diluted earnings per share to $6.84. The company experienced solid revenue growth of 6.4%, driven by increased demand for services, improved payer mix, and consistent patient acuity levels. HCA Healthcare Inc (NYSE:HCA) improved quality outcomes, throughput measures in emergency rooms, and patient satisfaction during the quarter. The company increased its 2025 guidance, reflecting a positive demand environment and the effectiveness of strategic initiatives. HCA Healthcare Inc (NYSE:HCA) maintained a strong balance sheet and executed a balanced capital allocation strategy, including $4.2 billion in cash flow from operations and $2.5 billion in share repurchases. Negative Points Medicaid volumes were down slightly, and self-pay volumes were below expectations, representing the lowest reimbursing payers. The company anticipates some people will lose insurance coverage due to the expiration of enhanced premium tax credits, which could impact financial performance. HCA Healthcare Inc (NYSE:HCA) faces challenges from the One Big Beautiful Bill Act, which includes potential adverse impacts from Medicaid components and exchange provisions. The company experienced underperformance in a couple of markets, which offset some of the better performance in hurricane-affected markets. Supply expenses increased slightly as a percentage of revenue due to increased spending on cardiac-related devices. Q & A Highlights Q: Can you elaborate on the guidance update, particularly regarding the Tennessee DPP program and the modest tweak on admissions numbers? A: Michael Marks, CFO, explained that the $300 million increase in guidance is split equally between state supplemental payment programs, including the new Tennessee program, and better-than-expected performance in their portfolio. The Tennessee program is expected to start contributing cash in the latter half of the year. The admissions number was adjusted due to lower-than-expected Medicaid and self-pay volumes, but overall, the portfolio is performing well. Q: Could you provide more details on your resiliency programs, especially in light of the potential expiration of subsidies? A: Michael Marks stated that HCA is developing resiliency programs to offset potential adverse impacts from the expiration of enhanced premium tax credits (EPTCs). These efforts include benchmarking corporate departments, operational improvements, and leveraging automation and digital transformation. More details will be provided in the fourth-quarter earnings call. Q: What are you seeing in terms of commercial volume trends, and how might consumer confidence affect this? A: Michael Marks noted that managed care equivalent admissions are up 4% year-to-date, aligning with expectations. Exchange volumes are slightly better than expected, while traditional commercial volumes are slightly below. CEO Sam Hazen added that healthcare demand appears inelastic, and they haven't observed significant changes in consumer confidence affecting volumes. Q: How is HCA managing market share and local market dynamics, especially with high utilization rates reported by payers? A: CEO Sam Hazen highlighted sustained market share gains across service lines and markets. HCA is investing in network integrity and capacity to meet demand and achieve share gains. Despite some competitive dynamics, HCA remains agile and confident in its market positioning. Q: Can you provide insights into the impact of the One Big Beautiful Bill Act and the expiration of EPTCs on long-term guidance? A: Michael Marks stated that HCA's financial resiliency program should offset near-term impacts from the Act's exchange provisions. Long-term, HCA expects to manage impacts through phased reforms and potential supplemental payment approvals. The outcome of EPTCs is uncertain, but HCA is preparing resiliency plans to mitigate adverse effects. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
41 minutes ago
- Yahoo
Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 17, Morgan Stanley upgraded FOLD to Overweight with a $12 price target, citing its strong intellectual property position ahead of a key legal decision with Aurobindo. A research team in lab coats testing a new ImmunoPhage platform in a modern biotechnology lab. The firm also pointed to Amicus's solid financials—including a 90.6% gross margin and a current ratio of 3.34—and growing confidence in patient shifts toward PomOp over Nexviazyme/Lumizyme. Morgan Stanley adjusted its sales forecasts slightly below consensus for Galafold and PomOp, but remains bullish due to Amicus's recent licensing of DMX-200 for FSGS treatment. With strategic supply chain planning and U.S. inventory in place, management expects minimal tariff impact in 2025, reinforcing the company's operational resilience. Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a global biotechnology company that develops and delivers transformative medicines for people living with rare metabolic diseases. It leverages innovative technology platforms to create treatments for genetic diseases, with a strong emphasis on patient needs. While we acknowledge the potential of FOLD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
